Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and effectiveness of omalizumab in the treatment of childhood asthma.
Tortajada-Girbés M, Bousquet R, Bosque M, Carrera Martínez JJ, Ibáñez MD, Moreira A, Nieto A, Plaza AM, Rivas C, Requena G, Sánchez-Solis M, Tabar A, Torres-Borrego J, Zapatero L. Tortajada-Girbés M, et al. Among authors: torres borrego j. Expert Rev Respir Med. 2018 Sep;12(9):745-754. doi: 10.1080/17476348.2018.1507740. Epub 2018 Aug 28. Expert Rev Respir Med. 2018. PMID: 30141696 Review.
[Consensus-based approach for severe paediatric asthma in routine clinical practice].
Plaza AM, Ibáñez MD, Sánchez-Solís M, Bosque-García M, Cabero MJ, Corzo JL, García-Hernández G, de la Hoz B, Korta-Murua J, Sánchez-Salguero C, Torres-Borrego J, Tortajada-Girbés M, Valverde-Molina J, Zapatero L, Nieto A. Plaza AM, et al. An Pediatr (Barc). 2016 Feb;84(2):122.e1-122.e11. doi: 10.1016/j.anpedi.2015.08.015. Epub 2015 Oct 26. An Pediatr (Barc). 2016. PMID: 26515042 Free article. Spanish.
The influence of microorganisms in allergic diseases.
Tortajada-Girbés M, Torres-Borrego J. Tortajada-Girbés M, et al. Allergol Immunopathol (Madr). 2017 Nov-Dec;45(6):519-520. doi: 10.1016/j.aller.2017.10.001. Allergol Immunopathol (Madr). 2017. PMID: 29110881 No abstract available.
Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey.
Mondejar-Lopez P, Quintana-Gallego E, Giron-Moreno RM, Cortell-Aznar I, Ruiz de Valbuena-Maiz M, Diab-Caceres L, Prados-Sanchez C, Alvarez-Fernandez A, Garcia-Marcos PW, Peñalver-Mellado C, Pastor-Vivero MD, Olveira C, Lopez-Neyra A, Castillo-Corullon S, Palma-Milla S, Perez-Ruiz E, Sole-Jover A, Barrio MI, Sanchez-Solis M, Asensio de la Cruz Ó; CF-COVID19-Spain Registry Group. Mondejar-Lopez P, et al. Respir Med. 2020 Aug-Sep;170:106062. doi: 10.1016/j.rmed.2020.106062. Epub 2020 Jun 8. Respir Med. 2020. PMID: 32843180 Free PMC article.
Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma.
Nieto García A, Garriga-Baraut T, Plaza Martín AM, Nieto Cid M, Torres Borrego J, Folqué Giménez MDM, Lozano Blasco J, Bosque García M, Moreno-Galarraga L, Tortajada-Girbés M, Rivas Juesas C, Penín Antón M, Caballero-Rabasco MA, Gaboli M, López Neyra A, Navarro Morón J, Freixa Benavente A, Valdesoiro Navarrete L, Ballester Asensio E, Sanz Santiago V, Romero García R, Gimeno Díaz de Atauri Á, Valenzuela Soria A, Sánchez Mateos M, Batlles Garrido J, Andrés Martín A, Campos Alonso E, Aragón Fernández C, Vázquez Rodríguez E, Martínez Pardo L, Del-Río Camacho G, Mazón Ramos Á. Nieto García A, et al. Among authors: torres borrego j. Pediatr Allergy Immunol. 2021 Jul;32(5):980-991. doi: 10.1111/pai.13484. Epub 2021 Mar 20. Pediatr Allergy Immunol. 2021. PMID: 33619748
Transition of Adolescents With Severe Asthma From Pediatric to Adult Care in Spain: The STAR Consensus.
Valverde-Molina J, Fernández-Nieto M, Torres-Borrego J, Lozano Blasco J, de Mir-Messa I, Blanco-Aparicio M, Nieto A, Figuerola Mulet J, Moure AL, Sánchez-Herrero MG, Sánchez-García S. Valverde-Molina J, et al. Among authors: torres borrego j. J Investig Allergol Clin Immunol. 2023 Jun 15;33(3):179-189. doi: 10.18176/jiaci.0780. Epub 2022 Jan 14. J Investig Allergol Clin Immunol. 2023. PMID: 35029151 Free article.
Cost-effectiveness of omalizumab for the treatment of severe pediatric allergic asthma-Results of a real-life study in Spain.
Nieto-Cid M, Garriga-Baraut T, Plaza-Martín AM, Tortajada-Girbés M, Torres-Borrego J, Lozano-Blasco J, Moreno-Galarraga L, Del Mar Folqué-Giménez M, Bosque-García M, Gaboli M, López-Neyra A, Rivas-Juesas C, Caballero-Rabasco MA, Freixa-Benavente A, Valdesoiro-Navarrete L, de Mir-Messa I, Ballester-Asensio E, Penín-Antón M, Romero-García R, Navarro-Morón J, Valenzuela-Soria A, Sánchez-Mateos M, Batlles-Garrido J, Sanz-Santiago V, de Atauri ÁG, Andrés-Martín A, Campos-Alonso E, Gómez-Pastrana D, Vázquez-Rodríguez E, Martínez-Pardo L, Del Río-Camacho G, Mazón-Ramos Á, Nieto-García A. Nieto-Cid M, et al. Among authors: torres borrego j. Pediatr Allergy Immunol. 2023 Apr;34(4):e13942. doi: 10.1111/pai.13942. Pediatr Allergy Immunol. 2023. PMID: 37102393
Dissecting Airborne Allergens.
Torres-Borrego J, Sánchez-Solís M. Torres-Borrego J, et al. J Clin Med. 2023 Sep 8;12(18):5856. doi: 10.3390/jcm12185856. J Clin Med. 2023. PMID: 37762797 Free PMC article. Review.
36 results